Company news

Iovance Biotherapeutics, Inc. news in 2020

Iovance Biotherapeutics, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Iovance Biotherapeutics Appoints Jean-Marc Bellemin as Chief Financial Officer

December 13, 2020

Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2020 Financial Results and Corporate Updates

November 4, 2020

Iovance Biotherapeutics Provides Update for Lifileucel in Metastatic Melanoma

October 4, 2020

Iovance Biotherapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate Update

August 5, 2020

Iovance Biotherapeutics, Inc. Announces Closing of $603.7 Million Common Stock Public Offering

June 1, 2020

Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $525 Million of Common Stock

May 27, 2020

Iovance Reports Pivotal Cohort 4 Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel from C-144-01 Clinical Study in Advanced Melanoma

May 26, 2020

Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma

May 12, 2020

Iovance Biotherapeutics Reports First Quarter 2020 Financial Results and Provides a Corporate Update

May 4, 2020

Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update

February 24, 2020

Iovance Biotherapeutics Completes Patient Dosing in Registration-Enabling Cohort 4 of the C-144-01 Melanoma Study with Lifileucel

January 14, 2020

Iovance Biotherapeutics Obtains License to Develop and Commercialize a Novel IL-2 Analog

January 11, 2020

Decks in 2020